Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Employees140,800IPONov 8, 1996SIC2834HQOne Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
to
Financials (EUR)
Profitability
Metric
Current
Margins
Gross Margin
67.9%
Operating Margin
27.2%
EBITDA Margin
43.6%
Net Margin
28.5%
OCF Margin
—
FCF Margin
20.4%
Returns on Capital
ROE
34.5%
ROA
14.0%
ROIC
14.4%
ROCE
24.2%
ROC (Greenblatt)
154.1%
3Y ROIIC
64.0%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
21.69
Forward P/E
20.98
P/E ex-NRI
22.19
Shiller P/E (CAPE)
30.64
Cash Flow Multiples
P/FCF
30.16
P/OCF
23.74
P/Owner Earnings
31.41
FCF Yield
3.32%
Enterprise Value Multiples
EV / EBIT
18.14
EV / Forward EBIT
18.43
EV / EBITDA
14.82
EV / Forward EBITDA
16.20
EV / Revenue
6.46
EV / Forward Revenue
6.04
Asset / Sales
P/S
6.18
P/B
7.08
P/Tangible Book
—
Growth-Adjusted
PEG
2.36
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
2.19%
Forward Dividend Yield
2.17%
3Y Dividend Growth
4.9%
Payout Ratio
0.48
5Y Yield on Cost
2.81%
Buybacks & Dilution
3Y Buyback Ratio
2.70%
5Y Share Change
−9.1%
Combined
Shareholder Yield
1.07%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
0.59
Gross Debt / EBITDA
1.17
Cash / Debt
0.42
Equity / Assets
0.41
Coverage
Interest Coverage
26.36
Short-Term Liquidity
Current Ratio
1.03
Quick Ratio
0.77
Cash Ratio
0.37
Composite Scores
Piotroski F-Score
3
Altman Z-Score
3.98
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-02-24
$1.3
2026-03-10
2025-11-25
$1.3
2025-12-09
2025-08-26
$1.3
2025-09-09
2025-05-27
$1.3
2025-06-10
2025-02-18
$1.24
2025-03-04
2024-11-26
$1.24
2024-12-10
2024-08-27
$1.24
2024-09-10
2024-05-20
$1.24
2024-06-04
2024-02-16
$1.19
2024-03-05
2023-11-20
$1.19
2023-12-05
10 of 155
View allDate
Transcript
Type
2026-08-03
Johnson & Johnson Investor Conference Call Transcript
Corporate Presentation
2026-07-15
Q2 2026 Johnson & Johnson Earnings Call Transcript
Earnings Call
2026-06-09
Johnson & Johnson at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-27
Johnson & Johnson at Bernstein Strategic Decisions Conference Transcript
Conference Presentations
2026-05-19
Johnson & Johnson at RBC Capital Markets Global Healthcare Conference Transcript
Conference Presentations
2026-05-12
Johnson & Johnson at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-04-14
Q1 2026 Johnson & Johnson Earnings Call Transcript
Earnings Call
2026-03-10
Johnson & Johnson at Barclays Global Healthcare Conference Transcript
Conference Presentations
2026-03-03
Johnson & Johnson at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-01-21
Q4 2025 Johnson & Johnson Earnings Call Transcript
Earnings Call
10 of 111
5-Step DuPont Analysis
ROE %
34.42%
×
×
Net Margin %
28.85%
×
×
Operating Margin %
27.20%
Operating Income
€22.37B
÷
Revenue
€82.26B
×
Tax Burden
0.8223
Net Income
€23.73B
÷
Pretax Income
€28.86B
×
Interest Burden
1.2901
Pretax Income
€28.86B
÷
Operating Income
€22.37B
×
Asset Turnover
0.48
÷
Revenue
€82.26B
÷
Average Total Assets
€171.06B
Begin Total Assets
€172.00B
End Total Assets
€170.13B
×
Equity Multiplier
2.48
÷
Avg Total Assets
€171.06B
÷
Avg Stockholders Equity
€68.96B
Begin Equity
€68.27B
End Equity
€69.64B